Alberto Gandolfi from Goldman Sachs retains his positive opinion on the stock with a Buy rating. The target price has been modified and is now set at CHF 106 compared to CHF 107. | October 5, 2022
In a research note published by Michael Leuchten, UBS gives a Neutral rating to the stock. The target price is revised downwards from CHF 86 to CHF 80. | September 26, 2022
First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal. | June 30, 2022